Navigation Links
Appealing the death sentence for brain cells
Date:5/29/2008

A new drug candidate discovered by Tel Aviv University researcher Prof. Illana Gozes may lead to an effective treatment against the debilitative Alzheimer's disease. This compound could also treat a number of diseases where patients suffer from cognitive deficits, such as schizophrenia and Parkinson's, by limiting damage to the brain.

The new drug candidate, known as AL-108, was found to protect American patients with mild cognitive damage against memory loss by protecting the skeleton and transport system of brain cells. The new drug candidate has passed its Phase II clinical studies in U.S. Food and Drug Administration approved clinical trials. AL-108 is currently being developed by the Canada-based Allon Therapeutics Inc.

An Emphasis on Living Brain Cells

"My logic is that if you try to protect a dead cell, it won't work. We need to protect the living cell between the death sentence of having Alzheimer's and actual cell death," says Prof. Gozes. Her discovery, now the drug candidate AL-108, provides nerve cell protection. Publications reporting on the efficacy of AL-108 in animal models have appeared in the Journal of Pharmacology and Experimental Therapeutics, Journal of Molecular Neuroscience, the Journal of Biological Chemistry and many more.

Prof. Gozes, a co-founder of Allon Therapeutics and the company's Chief Scientific Officer, targeted support cells in the brain known as glia, which make up the majority of cells in the brain and are those that facilitate brain repair. She hypothesized that proteins produced by glia, and responsive to brain injury, may be able to repair the damage caused by neurodegenerative diseases such as Alzheimer's.

Like Train Rails Without Ties

Prof. Gozes and her team discovered a protein (ADNP) involved in brain repair, but if developed into a drug it would be too large to cross the blood-brain barrier. Cutting the protein into fragments, Prof. Gozes determined a small portion of the protein (NAP) provides potent neuroprotection by protecting nerve cells against severe oxidative stress and the toxicity associated with diseases such as Alzheimer's. AL-108, the drug candidate under development now, is an intranasal formulation based on NAP.

What happens in the nerve cells of Alzheimer's brains can be likened to a derailed train, says Prof. Gozes. The nerve cell skeleton the microtubules are like the rails, and a protein called "tau" functions like the ties between the rails. In Alzheimer's, the ties fall off, the tracks fall apart and nerve cells die. AL-108 however, seems to prevent this process from accelerating.

AL-108, which could be ready in as early as 5 years, targets the microtubules and protects against amyloid plaques a characteristic of Alzheimer's disease. AL-108 also seems to be able to maintain brain microtubule functioning, preventing memory loss and the deterioration of other cognitive functions, such as learning abilities, in those whose mental functioning has already started to decline.

"It's important to stress that these are drug candidates in clinical development in North America for now, and will not be ready for several years," says Prof. Gozes, who co-founded Allon Therapeutics with Tel Aviv University's technology transfer arm Ramot.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. World Vision Appealing for $2 Million for Deadly China Quake
2. Exercise cuts cancer death in men
3. Air Bags-Seat Belts Cut Injuries, Deaths, Costs
4. Educational Drive Cut Death Rate From Sepsis
5. Men at increased risk of death from pneumonia compared to women
6. Hidden heart condition increases the risk of death in patients waiting for kidney transplants
7. Biomarkers Predict Heart Deaths
8. Death Gap Widens Between Educated and Those Not
9. Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. Beta Blockers Raise Stroke, Death Risk After Surgery
11. Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Appealing the death sentence for brain cells
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Today, ... optimize the ingestion of their medication by matching users with high quality water pipes ... compare pieces with no commitment. , Inhale was founded by two brothers, Nick and ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: